دورية أكاديمية
Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
| العنوان: | Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint? |
|---|---|
| المؤلفون: | Shukla, Bhavarth S, Shelburne, Samuel, Reyes, Katherine, Kamboj, Mini, Lewis, Jessica D, Rincon, Sandra L, Reyes, Jinnethe, Carvajal, Lina P, Panesso, Diana, Sifri, Costi D, Zervos, Marcus J, Pamer, Eric G, Tran, Truc T, Adachi, Javier, Munita, Jose M, Hasbun, Rodrigo, Arias, Cesar A |
| المصدر: | Infectious Diseases Articles |
| بيانات النشر: | Henry Ford Health Scholarly Commons |
| سنة النشر: | 2016 |
| المجموعة: | Henry Ford Health System Scholarly Commons |
| مصطلحات موضوعية: | Anti-Bacterial Agents, Bacteremia, Daptomycin, Drug Resistance, Bacterial, Enterococcus faecium, Female, Gram-Positive Bacterial Infections, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies |
| الوصف: | BACKGROUND: Daptomycin has become a front-line antibiotic for multidrug-resistant Enterococcus faecium bloodstream infections (BSIs). We previously showed that E. faecium strains with daptomycin minimum inhibitory concentrations (MICs) in the higher end of susceptibility frequently harbor mutations associated with daptomycin resistance. We postulate that patients with E. faecium BSIs exhibiting daptomycin MICs of 3-4 µg/mL treated with daptomycin are more likely to have worse clinical outcomes than those exhibiting daptomycin MICs ≤2 µg/mL. METHODS: We conducted a multicenter retrospective cohort study that included adult patients with E. faecium BSI for whom initial isolates, follow-up blood culture data, and daptomycin administration data were available. A central laboratory performed standardized daptomycin MIC testing for all isolates. The primary outcome was microbiologic failure, defined as clearance of bacteremia ≥4 days after the index blood culture. The secondary outcome was all-cause in-hospital mortality. RESULTS: A total of 62 patients were included. Thirty-one patients were infected with isolates that exhibited daptomycin MICs of 3-4 µg/mL. Overall, 34 patients had microbiologic failure and 25 died during hospitalization. In a multivariate logistic regression model, daptomycin MICs of 3-4 µg/mL (odds ratio [OR], 4.7 [1.37-16.12]; P = .014) and immunosuppression (OR, 5.32 [1.20-23.54]; P = .028) were significantly associated with microbiologic failure. Initial daptomycin dose of ≥8 mg/kg was not significantly associated with evaluated outcomes. CONCLUSIONS: Daptomycin MICs of 3-4 µg/mL in the initial E. faecium blood isolate predicted microbiological failure of daptomycin therapy, suggesting that modification in the daptomycin breakpoint for enterococci should be considered. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://scholarlycommons.henryford.com/infectiousdiseases_articles/75Test; http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:27045126Test |
| الإتاحة: | https://scholarlycommons.henryford.com/infectiousdiseases_articles/75Test http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:27045126Test |
| رقم الانضمام: | edsbas.182516F9 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.182516F9 800 3 Academic Journal academicJournal 799.776672363281 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.182516F9&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://scholarlycommons.henryford.com/infectiousdiseases_articles/75# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Shukla%2C+Bhavarth+S%22">Shukla, Bhavarth S</searchLink><br /><searchLink fieldCode="AR" term="%22Shelburne%2C+Samuel%22">Shelburne, Samuel</searchLink><br /><searchLink fieldCode="AR" term="%22Reyes%2C+Katherine%22">Reyes, Katherine</searchLink><br /><searchLink fieldCode="AR" term="%22Kamboj%2C+Mini%22">Kamboj, Mini</searchLink><br /><searchLink fieldCode="AR" term="%22Lewis%2C+Jessica+D%22">Lewis, Jessica D</searchLink><br /><searchLink fieldCode="AR" term="%22Rincon%2C+Sandra+L%22">Rincon, Sandra L</searchLink><br /><searchLink fieldCode="AR" term="%22Reyes%2C+Jinnethe%22">Reyes, Jinnethe</searchLink><br /><searchLink fieldCode="AR" term="%22Carvajal%2C+Lina+P%22">Carvajal, Lina P</searchLink><br /><searchLink fieldCode="AR" term="%22Panesso%2C+Diana%22">Panesso, Diana</searchLink><br /><searchLink fieldCode="AR" term="%22Sifri%2C+Costi+D%22">Sifri, Costi D</searchLink><br /><searchLink fieldCode="AR" term="%22Zervos%2C+Marcus+J%22">Zervos, Marcus J</searchLink><br /><searchLink fieldCode="AR" term="%22Pamer%2C+Eric+G%22">Pamer, Eric G</searchLink><br /><searchLink fieldCode="AR" term="%22Tran%2C+Truc+T%22">Tran, Truc T</searchLink><br /><searchLink fieldCode="AR" term="%22Adachi%2C+Javier%22">Adachi, Javier</searchLink><br /><searchLink fieldCode="AR" term="%22Munita%2C+Jose+M%22">Munita, Jose M</searchLink><br /><searchLink fieldCode="AR" term="%22Hasbun%2C+Rodrigo%22">Hasbun, Rodrigo</searchLink><br /><searchLink fieldCode="AR" term="%22Arias%2C+Cesar+A%22">Arias, Cesar A</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Infectious Diseases Articles ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Henry Ford Health Scholarly Commons ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2016 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Henry Ford Health System Scholarly Commons ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Anti-Bacterial+Agents%22">Anti-Bacterial Agents</searchLink><br /><searchLink fieldCode="DE" term="%22Bacteremia%22">Bacteremia</searchLink><br /><searchLink fieldCode="DE" term="%22Daptomycin%22">Daptomycin</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Resistance%22">Drug Resistance</searchLink><br /><searchLink fieldCode="DE" term="%22Bacterial%22">Bacterial</searchLink><br /><searchLink fieldCode="DE" term="%22Enterococcus+faecium%22">Enterococcus faecium</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Gram-Positive+Bacterial+Infections%22">Gram-Positive Bacterial Infections</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Microbial+Sensitivity+Tests%22">Microbial Sensitivity Tests</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+Studies%22">Retrospective Studies</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => BACKGROUND: Daptomycin has become a front-line antibiotic for multidrug-resistant Enterococcus faecium bloodstream infections (BSIs). We previously showed that E. faecium strains with daptomycin minimum inhibitory concentrations (MICs) in the higher end of susceptibility frequently harbor mutations associated with daptomycin resistance. We postulate that patients with E. faecium BSIs exhibiting daptomycin MICs of 3-4 µg/mL treated with daptomycin are more likely to have worse clinical outcomes than those exhibiting daptomycin MICs ≤2 µg/mL. METHODS: We conducted a multicenter retrospective cohort study that included adult patients with E. faecium BSI for whom initial isolates, follow-up blood culture data, and daptomycin administration data were available. A central laboratory performed standardized daptomycin MIC testing for all isolates. The primary outcome was microbiologic failure, defined as clearance of bacteremia ≥4 days after the index blood culture. The secondary outcome was all-cause in-hospital mortality. RESULTS: A total of 62 patients were included. Thirty-one patients were infected with isolates that exhibited daptomycin MICs of 3-4 µg/mL. Overall, 34 patients had microbiologic failure and 25 died during hospitalization. In a multivariate logistic regression model, daptomycin MICs of 3-4 µg/mL (odds ratio [OR], 4.7 [1.37-16.12]; P = .014) and immunosuppression (OR, 5.32 [1.20-23.54]; P = .028) were significantly associated with microbiologic failure. Initial daptomycin dose of ≥8 mg/kg was not significantly associated with evaluated outcomes. CONCLUSIONS: Daptomycin MICs of 3-4 µg/mL in the initial E. faecium blood isolate predicted microbiological failure of daptomycin therapy, suggesting that modification in the daptomycin breakpoint for enterococci should be considered. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => text ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => unknown ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://scholarlycommons.henryford.com/infectiousdiseases_articles/75; http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:27045126 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://scholarlycommons.henryford.com/infectiousdiseases_articles/75<br />http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:27045126 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.182516F9 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => unknown
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Anti-Bacterial Agents
[Type] => general
)
[1] => Array
(
[SubjectFull] => Bacteremia
[Type] => general
)
[2] => Array
(
[SubjectFull] => Daptomycin
[Type] => general
)
[3] => Array
(
[SubjectFull] => Drug Resistance
[Type] => general
)
[4] => Array
(
[SubjectFull] => Bacterial
[Type] => general
)
[5] => Array
(
[SubjectFull] => Enterococcus faecium
[Type] => general
)
[6] => Array
(
[SubjectFull] => Female
[Type] => general
)
[7] => Array
(
[SubjectFull] => Gram-Positive Bacterial Infections
[Type] => general
)
[8] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[9] => Array
(
[SubjectFull] => Male
[Type] => general
)
[10] => Array
(
[SubjectFull] => Microbial Sensitivity Tests
[Type] => general
)
[11] => Array
(
[SubjectFull] => Middle Aged
[Type] => general
)
[12] => Array
(
[SubjectFull] => Retrospective Studies
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shukla, Bhavarth S
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shelburne, Samuel
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Reyes, Katherine
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kamboj, Mini
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lewis, Jessica D
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rincon, Sandra L
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Reyes, Jinnethe
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Carvajal, Lina P
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Panesso, Diana
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sifri, Costi D
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zervos, Marcus J
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pamer, Eric G
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tran, Truc T
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Adachi, Javier
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Munita, Jose M
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hasbun, Rodrigo
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Arias, Cesar A
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2016
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Infectious Diseases Articles
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |